In 18 clinical studies of various topical formulations of clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatological events (see table below).
|
Treatment Emergent
Adverse Event |
Solution
n=553 (%) |
Gel
n=148 (%) |
Lotion
n=160 (%) |
|
Burning
|
62 (11)
|
15 (10)
|
17 (11)
|
|
Itching
|
36 (7)
|
15 (10)
|
17 (11)
|
|
Burning/Itching
|
60 (11)
|
# (-)
|
# (-)
|
|
Dryness
|
105 (19)
|
34 (23)
|
29 (18)
|
|
Erythema
|
86 (16)
|
10 (7)
|
22 (14)
|
|
Oiliness/Oily Skin
|
8 (1)
|
26 (18)
|
12 * (10)
|
|
Peeling
|
61 (11)
|
# (-)
|
11 (7)
|
|
# not recorded
* of 126 subjects |
|||